4DMedical company profile
Company profile
4DMedical has 181 employees and is headquartered in Carlton, Australia.
Pharmaceutical developers, clinical researchers and lung-health programmes in the United States and Australia are the core of the market served by 4DMedical Limited, a medical technology company that develops non-invasive respiratory imaging. Its range includes CT:VQ, a non-contrast post-processing technology, CAC for non-contrast cardiothoracic risk assessment, LDAi for automated detection of potential emphysema, and the XV Scanner, a lung function scanner. Its XV LVAS and CT LVAS software image lung airflow and regional lung function. The company has a contract with GlaxoSmithKline to supply quantitative lung imaging analytics for pulmonary drug development and clinical research, and a partnership with AstraZeneca on screening.
In the fiscal year ended 30 June 2026, revenue was AUD 7.1 million, up 20.6% from the prior year, and the net loss was AUD 204.4 million. The company had 181 employees and is headquartered in Carlton, Australia, where it was incorporated in 2012.
Company facts
- Sector
- Technology
- Industry
- Health Information Services
- Country
- Australia
- Headquarters
- Melbourne Connect, 3053, Carlton
- Employees
- 181
- Chief executive
- Andreas Fouras
- Founded
- 2012
- Fiscal year
- July - June
- Listing
- 4DX · ASX
- Indices
- S&P/ASX 200
- Currency
- AUD
- ISIN
- AU0000095416
- Website
- 4dmedical.com
4DMedical and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| 4DMedical4DX | Australia | $867.27M | 181 | -813.7% | — |
| XtalPi Holdings2228 | Hong Kong SAR China | $3B | 1,623 | -124.6% | — |
| M32413 | Japan | $7.04B | 17,010 | 19.5% | 24.4 |
| Pro MedicusPME | Australia | $13.08B | 153 | 74.9% | 76.0 |
| DoximityDOCS | United States | $5.13B | 880 | 27.1% | 39.9 |
| Tempus AITEM | United States | $9.86B | 3,800 | -18.5% | — |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
